Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 4/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.42 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL155194 | 1.00 | CYP1A2 (0.48) | CYP1A2CYP2A6CA2CYP3A4CYP2C19 | |
| SCHEMBL28744947 | 0.94 | CA2 (0.45) | CYP1A2CYP2A6CA2CYP3A4CYP2C19 | |
| SCHEMBL154909 | 0.83 | BACE1 (0.52) | CYP1A2CYP2A6CA2BACE1HSD17B1 | |
| SCHEMBL14609319 | 0.79 | MRGPRX4 (0.42) | CYP2A6CA2MRGPRX4SLC6A2SLC6A4 | |
| SCHEMBL28744573 | 0.79 | CA2 (0.50) | CYP1A2CYP2A6CA2BACE1MRGPRX4 | |
| SCHEMBL827314 | 0.79 | PARP10 (0.44) | CA2MRGPRX4POLBKMT2ACA12 | |
| SCHEMBL827195 | 0.79 | MAPT (0.50) | CYP1A2CA2CYP3A4CYP2C19MRGPRX4 | |
| SCHEMBL3794893 | 0.79 | MRGPRX4 (0.40) | CYP1A2CYP2A6CA2CYP3A4MRGPRX4 | |
| SCHEMBL15962630 | 0.76 | CYP1A2 (0.46) | CYP1A2CYP2A6CA2BACE1HSD17B1 | |
| SCHEMBL15495650 | 0.76 | CA2 (0.52) | CA2CYP3A4MRGPRX4POLBCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250108123-A1 | COMPOUND-LINKER CONSTRUCTS COMPRISING NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2025-04-03 | — | — | US | disclosed |
| CN-119161384-A | Estrogen receptor modulating compounds | 雷迪厄斯制药公司 | 2024-12-20 | — | — | CN | disclosed |
| CN-116813603-B | Selective estrogen receptor alpha degradation compound and preparation method and application thereof | 成都市第三人民医院 | 2024-10-22 | — | — | CN | disclosed |
| CN-112105607-B | Estrogen receptor modulating compounds | 雷迪厄斯制药公司 | 2024-08-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250108123-A1 | COMPOUND-LINKER CONSTRUCTS COMPRISING NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | STING1, IRF3, CGAS | CYP1A2 3438/4885CYP2A6 4319/4885CA2 4028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.